The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

WCLC 2022 | Targeting KRAS in lung cancer

Name: Targeting KRAS in lung cancer
Uploaded: 2022-08-07T00:00:00Z
Duration: 48 s
Description: Jong Woo Lee, MD, PhD, Yale Cancer Center and Yale University School of Medicine, New Haven, CT, talks on targeting KRAS in lung cancer. Based on research, combining Aurora Kinase A (ARUKA) inhibition with WEE1 inhibition can potentiate the inhibition of KRAS in lung cancer. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.

Jong Woo Lee • 7 Aug 2022

WCLC 2022

Lung Cancer

Jong Woo Lee, MD, PhD, Yale Cancer Center and Yale University School of Medicine, New Haven, CT, talks on targeting KRAS in lung cancer. Based on research, combining Aurora Kinase A (ARUKA) inhibition with WEE1 inhibition can potentiate the inhibition of KRAS in lung cancer. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.